NCT00138606已完成3 期
Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 179
- 试验地点
- 3
- 主要终点
- Change from baseline in HbA1c at 52 weeks
研究概览
简要总结
Many people with type 2 diabetes cannot maintain their target blood glucose levels on a single therapy. This is a 28-week extension to a study to assess the safety and effectiveness of vildagliptin, an unapproved drug, in lowering overall blood glucose levels when added to insulin in people with type 2 diabetes who are not at target blood glucose levels on insulin alone. The purpose of the extension study is to gather data on the long-term safety and effectiveness of vildagliptin in people with type 2 diabetes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Only patients successfully completing study CLAF237A2311 are eligible
- •Written informed consent
- •Ability to comply with all study requirements
排除标准
- •Premature discontinuation from CLAF237A2311
- •Other protocol-defined exclusion criteria may apply
结局指标
主要结局
Change from baseline in HbA1c at 52 weeks
Safety of vildagliptin in combination with insulin during 52 weeks of treatment
次要结局
- Change in HbA1c between 24 weeks and 52 weeks
- Change from baseline in mean daily number of insulin injections at 52 weeks
- Change in fasting plasma glucose between 24 weeks and 52 weeks
- Change from baseline in fasting plasma glucose at 52 weeks
- Change from baseline in mean daily insulin dose at 52 weeks
研究者
研究点 (3)
Loading locations...
相似试验
已完成
3 期
Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT00138515Novartis418
已完成
3 期
Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT00138554Novartis318
已完成
3 期
Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT00138580Novartis345
撤回
3 期
DiaFrail: A Short Duration Study in Older People ( DIAFRAIL Study)Diabetes MellitusNCT02484209Diabetes Frail Ltd
已完成
3 期
Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT00099931Novartis Pharmaceuticals254